Keith Leung, MD
Hematology & Oncology · Renton, WANPI 1306032446
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $417 of the $525 with a category attached, or 79.4%. It is spread thinly across 13 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $320, 3.1 times the $103 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.
Across 20 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$117
- AstraZeneca$87
- AbbVie$64
- Pfizer$46
- E.r. Squibb & Sons, L.L.C.$45
- Johnson & Johnson$43
- plus $123 from 7 others
What the payments were for
- Food & beverage$41779%
- Education$10821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 2 | $117 |
| AstraZeneca | 3 | $87 |
| AbbVie | 3 | $64 |
| Pfizer | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $45 |
| Johnson & Johnson | 1 | $43 |
| Tempus AI, Inc | 1 | $23 |
| Foundation Medicine, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Gilead | 1 | $12 |
How this compares
$525 in reported general payments places this provider in the 40th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 41 | $817,493 |
| ImbruvicaIbrutinib | 43 | $723,885 |
| IbrancePalbociclib | 43 | $653,786 |
| PomalystPomalidomide | 33 | $550,912 |
| JakafiRuxolitinib Phosphate | 21 | $418,977 |
| PromactaEltrombopag Olamine | 14 | $268,894 |
| VerzenioAbemaciclib | 20 | $217,657 |
| NinlaroIxazomib Citrate | 12 | $151,329 |
| Lenalidomide | 15 | $149,381 |
| CalquenceAcalabrutinib Maleate | 13 | $108,548 |
| BrukinsaZanubrutinib | 17 | $83,594 |
| EliquisApixaban | 58 | $47,654 |
| XareltoRivaroxaban | 58 | $45,488 |
| Fentanyl | 26 | $35,443 |
| AranespDarbepoetin Alfa In Polysorbat | 14 | $32,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $46 | $701,440101 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $45 | $550,91233 claims |
| Lilly USA, LLCVerzenio | $16 | $217,65720 claims |
| AstraZenecaCalquence | $87 | $108,54813 claims |
| Johnson & JohnsonXarelto | $43 | $45,48858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Renton
- Naixi ChenRenton$32K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.